alverine citrate and simeticone
DrugOther names: Meteospasmyl®
NCT Number: NCT00542295
To assess the effectiveness of alverine citrate and simeticone on IBS symptoms according to the latest recommended design
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 4
Budapest, Hungary
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other names: Meteospasmyl®
Time frame: Baseline and 4 weeks
Time frame: Baseline and 4 weeks
Laboratoires Mayoly Spindler
Industry
Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome. a 4-Week, Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase IV Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07722572
Anxiety Disorders, Colonic Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02136745
Colonic Diseases, Colonic Diseases, Functional
Boston, Massachusetts, United States
View Trial DetailsNCT06268717
Abdominal Pain, Alpha-Gal Syndrome
Chapel Hill, North Carolina, United States
View Trial DetailsNCT00742118
Colonic Diseases, Colonic Diseases, Functional
Nice, France
View Trial Details